<div id="readability-page-1"><div>NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Praxis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study. On this news, Praxis’s stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETXlOeU0zTURnM09UTXlJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETXlOeU0zTURnM09UTXlJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTRjNWYyNzQtYmI5Yy00Y2Q0LWI4ODctOWNlNDg3MmRjODVkLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTRjNWYyNzQtYmI5Yy00Y2Q0LWI4ODctOWNlNDg3MmRjODVkLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

PRAX

Pomerantz 律師事務所正在代表 Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX）的投資者調查有關該公司及其高管潛在證券欺詐的索賠。這一調查是由於 Praxis 最近的財務報告揭示其抗癲癇藥物的中期研究中出現不利事件，導致股價下跌 5.55%。鼓勵投資者聯繫 Pomerantz 以獲取有關加入集體訴訟的更多信息

投資者警報：Pomerantz 律師事務所正在代表 Praxis Precision Medicines, Inc.的投資者調查索賠 - PRAX